HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced that Anette Engelhardt will join the company as its new Executive Vice President and President of the Clinical Diagnostics Group, effective June 10, 2024..

加利福尼亚州赫拉克勒斯（商业新闻短讯）--生命科学研究和临床诊断产品的全球领导者Bio-Rad Laboratories，Inc.（纽约证券交易所：Bio and Bio.B）今天宣布，Anette Engelhardt将加入该公司，担任其新的执行副总裁兼临床诊断集团总裁，自2024年6月10日起生效。。

Ms. Engelhardt joins Bio-Rad from Cepheid, a wholly owned subsidiary of Danaher Corporation and a leading global molecular diagnostics company. While at Cepheid, Ms. Engelhardt was Senior Vice President and General Manager overseeing the emerging growth opportunities business, as well as Senior Vice President of global research and development, strategy, product management and marketing functions supporting the company’s extensive product portfolio..

Engelhardt女士从造父变星加入Bio-Rad，造父变星是Danaher Corporation的全资子公司，也是全球领先的分子诊断公司。在造父变星任职期间，恩格尔哈特女士担任高级副总裁兼总经理，负责监督新兴增长机会业务，并担任全球研发、战略、产品管理和营销职能高级副总裁，支持公司广泛的产品组合。。

Prior to Cepheid, Ms. Engelhardt held several senior positions at bioMerieux Inc., a global leader in in vitro diagnostics, including Senior Vice President of the company’s new technologies franchise and microbiology business unit. In these roles, she was responsible for developing and implementing product and market strategies for bioMerieux’s range of microbiology-related reagents, instruments, and services, as well as leveraging and commercializing new technologies.

在造父变星之前，恩格尔哈特女士曾在体外诊断领域的全球领导者bioMerieux Inc.担任过多个高级职位，包括该公司新技术特许经营和微生物学业务部门的高级副总裁。在这些职位上，她负责开发和实施bioMerieux系列微生物学相关试剂、仪器和服务的产品和市场战略，以及利用和商业化新技术。

Ms. Engelhardt’s career also includes tenure as CEO of privately held AB BIODISK, where she managed the in vitro diagnostics company’s post-acquisition integration into bioMerieux. She began her career as a process engineer at AB BIODISK and holds a combined Master of Science and Bachelor of Science degree in Chemical Engineering and Polymer Technology from the Royal Institute of Technology in Stockholm, Sweden..

恩格尔哈特女士的职业生涯还包括担任私人持有的AB BIODISK首席执行官，负责管理这家体外诊断公司收购后与bioMerieux的整合。她在AB BIODISK担任工艺工程师，拥有瑞典斯德哥尔摩皇家理工学院的化学工程和聚合物技术理学硕士和理学学士学位。。

“We are very pleased to welcome Anette Engelhardt as President of our Clinical Diagnostics Group,” stated Andy Last, Bio-Rad’s Executive Vice President and Chief Operating Officer. “Anette brings to Bio-Rad extensive operational experience and a successful track record in developing and commercializing novel diagnostics products across multiple markets.

Bio-Rad执行副总裁兼首席运营官安迪·拉斯特（AndyLast）表示：“我们非常高兴欢迎安妮特·恩格哈特（AnetteEngelhardt）担任我们临床诊断集团的总裁。“Anette为Bio-Rad带来了丰富的运营经验和在多个市场开发和商业化新型诊断产品的成功记录。

We are confident her expertise will help advance our clinical diagnostics strategy to extend Bio-Rad’s core diagnostics and develop new products and market entries for our clinical business.”.

我们相信她的专业知识将有助于推进我们的临床诊断策略，以扩展Bio-Rad的核心诊断，并为我们的临床业务开发新产品和市场进入。”。

About Bio-Rad

关于Bio-Rad

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B) is a leader in developing, manufacturing, and marketing a broad range of products for the life science research and clinical diagnostics markets. Based in Hercules, California, Bio-Rad operates a global network of research, development, manufacturing, and sales operations with over 8,000 employees and $2.7 billion in revenues in 2023.

Bio-Rad Laboratories，Inc.（纽约证券交易所：Bio and Bio.B）是为生命科学研究和临床诊断市场开发、制造和营销多种产品的领导者。Bio-Rad总部位于加利福尼亚州的大力神，拥有全球研发、制造和销售运营网络，2023年拥有8000多名员工和27亿美元的收入。

Our customers include universities, research institutions, hospitals, food safety and environmental quality laboratories, and biopharmaceutical companies. Together, we develop innovative, high-quality products that advance science and save lives. To learn more, visit bio-rad.com..

我们的客户包括大学、研究机构、医院、食品安全和环境质量实验室以及生物制药公司。我们共同开发创新、高质量的产品，以推进科学和拯救生命。要了解更多信息，请访问bio-rad.com。。

Forward-Looking Statements

前瞻性声明

This release may be deemed to contain certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, without limitation, statements we make regarding our products and our expectations about our products. Forward-looking statements generally can be identified by the use of forward-looking terminology such as 'plan,' 'believe,' 'expect,' 'anticipate,' 'may,' 'will,' 'intend,' 'estimate,' 'continue,' or similar expressions or the negative of those terms or expressions, although not all forward-looking statements contain these words.

本公告可能被视为包含1995年《私人证券诉讼改革法案》所指的某些前瞻性声明。这些前瞻性声明包括但不限于我们对产品的声明以及我们对产品的期望。前瞻性陈述通常可以通过使用前瞻性术语来识别，例如“计划”，“相信”，“期望”，“预期”，“可能”，“意志”，“打算”，“估计”，“继续”或类似的表达或这些术语或表达的否定，尽管并非所有前瞻性陈述都包含这些单词。

Such statements involve risks and uncertainties, which could cause actual results to vary materially from those expressed in or indicated by the forward-looking statements. These risks and uncertainties include global economic and geopolitical conditions, our ability to develop and market new or improved products, our ability to compete effectively, international legal and regulatory risks, supply chain risks, and product quality and liability issues.

此类声明涉及风险和不确定性，这可能导致实际结果与前瞻性声明中表达或指示的结果产生重大差异。这些风险和不确定性包括全球经济和地缘政治条件、我们开发和营销新产品或改进产品的能力、我们有效竞争的能力、国际法律和监管风险、供应链风险以及产品质量和责任问题。

For further information regarding our risks and uncertainties, please refer to the 'Risk Factors' and 'Management's Discussion and Analysis of Financial Condition and Results of Operation' in Bio-Rad's public reports filed with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K and our Quarterly Reports on Form 10-Q.

有关我们的风险和不确定性的更多信息，请参阅Bio-Rad向证券交易委员会提交的公开报告中的“风险因素”和“管理层对财务状况和经营成果的讨论和分析”，包括我们最近的10-K表年度报告和10-Q表季度报告。

Bio-Rad cautions you not to place undue reliance on forward-looking statements, which reflect an analysis only and speak only as of the date hereof. We disclaim any obligation to update these forward-looking statements..

Bio-Rad提醒您不要过度依赖前瞻性陈述，前瞻性陈述仅反映分析结果，仅在本报告发布之日起有效。我们不承担更新这些前瞻性声明的任何义务。。